Publicaciones en colaboración con investigadores/as de Hospital Miguel Servet (4)

2022

  1. Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 4, pp. 637-646

2021

  1. Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: A cost-effectiveness analysis

    Journal of Comparative Effectiveness Research, Vol. 10, Núm. 4, pp. 325-335

2019

  1. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: A cost-effectiveness analysis

    Journal of Comparative Effectiveness Research, Vol. 8, Núm. 11, pp. 853-863

2016

  1. Expression of aquaporins 1 and 5 in a model of ventilator-induced lung injury and its relation to tidal volume

    Experimental Physiology, Vol. 101, Núm. 11, pp. 1418-1431